Clinical TopicsInfection PreventionNeurologyWeb Exclusives

FDA announces new risk factor for PML associated with Tysabri

Share

On Jan. 20, the U.S. Food and Drug Administration (FDA) announced that testing positive for anti-JC virus antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection associated with use of Tysabri (natalizumab) for the treatment of multiple sclerosis or Crohn’s disease. Read more.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Test Your Knowledge

Which of the following is correct about the stages of sleep?

Recent Posts